JP2009541386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541386A5 JP2009541386A5 JP2009516964A JP2009516964A JP2009541386A5 JP 2009541386 A5 JP2009541386 A5 JP 2009541386A5 JP 2009516964 A JP2009516964 A JP 2009516964A JP 2009516964 A JP2009516964 A JP 2009516964A JP 2009541386 A5 JP2009541386 A5 JP 2009541386A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- acid
- alkoxy
- substituted
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- -1 1H-tetrazol-5-yl Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0612721.1A GB0612721D0 (en) | 2006-06-27 | 2006-06-27 | Organic compounds |
| PCT/EP2007/005597 WO2008000419A1 (en) | 2006-06-27 | 2007-06-25 | S1p receptor modulators for treating multiple sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013076909A Division JP2013166761A (ja) | 2006-06-27 | 2013-04-02 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541386A JP2009541386A (ja) | 2009-11-26 |
| JP2009541386A5 true JP2009541386A5 (enExample) | 2010-08-26 |
Family
ID=36888144
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516964A Pending JP2009541386A (ja) | 2006-06-27 | 2007-06-25 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2013076909A Pending JP2013166761A (ja) | 2006-06-27 | 2013-04-02 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2016087703A Withdrawn JP2016185957A (ja) | 2006-06-27 | 2016-04-26 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2018021389A Withdrawn JP2018109018A (ja) | 2006-06-27 | 2018-02-08 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2019089217A Active JP6931019B2 (ja) | 2006-06-27 | 2019-05-09 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2020176666A Active JP7258832B2 (ja) | 2006-06-27 | 2020-10-21 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2023061697A Pending JP2023098949A (ja) | 2006-06-27 | 2023-04-05 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2024172795A Pending JP2025016462A (ja) | 2006-06-27 | 2024-10-01 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013076909A Pending JP2013166761A (ja) | 2006-06-27 | 2013-04-02 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2016087703A Withdrawn JP2016185957A (ja) | 2006-06-27 | 2016-04-26 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2018021389A Withdrawn JP2018109018A (ja) | 2006-06-27 | 2018-02-08 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2019089217A Active JP6931019B2 (ja) | 2006-06-27 | 2019-05-09 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2020176666A Active JP7258832B2 (ja) | 2006-06-27 | 2020-10-21 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2023061697A Pending JP2023098949A (ja) | 2006-06-27 | 2023-04-05 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
| JP2024172795A Pending JP2025016462A (ja) | 2006-06-27 | 2024-10-01 | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20100168078A1 (enExample) |
| EP (4) | EP2698154A1 (enExample) |
| JP (8) | JP2009541386A (enExample) |
| KR (6) | KR20150122812A (enExample) |
| CN (2) | CN101478961B (enExample) |
| AU (7) | AU2007264031C1 (enExample) |
| BR (1) | BRPI0713985A2 (enExample) |
| CA (1) | CA2653569C (enExample) |
| DE (1) | DE15177166T1 (enExample) |
| DK (1) | DK2959894T3 (enExample) |
| ES (1) | ES2887042T3 (enExample) |
| GB (1) | GB0612721D0 (enExample) |
| HU (1) | HUE059922T4 (enExample) |
| LT (1) | LT2959894T (enExample) |
| MX (3) | MX2008016133A (enExample) |
| PL (1) | PL2959894T3 (enExample) |
| PT (1) | PT2959894T (enExample) |
| RU (1) | RU2617502C2 (enExample) |
| SI (1) | SI2959894T1 (enExample) |
| WO (1) | WO2008000419A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| KR101526835B1 (ko) * | 2007-05-04 | 2015-06-05 | 노파르티스 아게 | Ｓ1ｐ 수용체 조절제의 용도 |
| SG10201406263SA (en) * | 2008-06-20 | 2015-02-27 | Novartis Ag | Paediatric compositions for treating multiple sclerosis |
| RU2523281C2 (ru) * | 2008-08-18 | 2014-07-20 | Новартис Аг | Соединения для лечения периферических невропатий |
| EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
| KR20170062554A (ko) * | 2008-12-18 | 2017-06-07 | 노파르티스 아게 | 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염 |
| RU2011129230A (ru) * | 2008-12-18 | 2013-01-27 | Новартис Аг | Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты |
| CN103204794A (zh) * | 2008-12-18 | 2013-07-17 | 诺瓦提斯公司 | 新的盐 |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
| RU2012125184A (ru) * | 2009-11-24 | 2013-12-27 | Аллерган, Инк. | Новые соединения в качестве модуляторов рецепторов с терапевтическим действием |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| BR112013017302B1 (pt) | 2011-01-07 | 2021-12-07 | Novartis Ag | Composição farmacêutica em fase sólida |
| CN102120720B (zh) * | 2011-01-25 | 2013-05-22 | 上海华升生物科技有限公司 | 盐酸芬戈莫德的合成新方法 |
| MX2014004813A (es) * | 2011-10-21 | 2014-05-20 | Novartis Ag | Regimen de dosificacion para un modulador o agonista del receptor s1p. |
| EP2830338A4 (en) * | 2012-03-23 | 2015-12-30 | Nec Corp | SUBSCRIBER SERVER, MONITOR SERVER, MOBILE TERMINAL, ASSOCIATED METHOD AND COMPUTER READABLE MEDIUM |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
| WO2015053878A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| WO2017120124A1 (en) | 2016-01-04 | 2017-07-13 | Auspex Pharmaceuticals, Inc. | Azetidine modulators of the sphingosine 1-phosphate receptor |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| PH12022551043A1 (en) | 2019-10-31 | 2023-05-03 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| US20250177115A1 (en) * | 2021-08-20 | 2025-06-05 | The Brain Protection Company PTY LTD | Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB612721A (en) | 1946-02-11 | 1948-11-17 | Richard William Bailey | Improvements in combustion product power plant |
| DE122011100012I1 (de) | 1992-10-21 | 2011-10-20 | Mitsubishi Tanabe Pharma Corp | 2-Amino-1, 3-propandiolverbindung und immunosuppressium. |
| ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
| WO1996006068A1 (en) | 1994-08-22 | 1996-02-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and medicinal use thereof |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| IL155065A (en) | 1997-04-04 | 2004-01-04 | Mitsubishi Pharma Corp | History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| DE69926536T3 (de) | 1998-12-22 | 2013-09-12 | Genentech, Inc. | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| CA2366857C (en) | 1999-03-30 | 2010-12-14 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| AU2001231710A1 (en) | 2000-02-09 | 2001-08-20 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| DE10033541C2 (de) | 2000-07-11 | 2003-05-15 | Litef Gmbh | Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung |
| CN1267429C (zh) | 2000-07-13 | 2006-08-02 | 三共株式会社 | 氨基醇衍生物 |
| CA2421893A1 (en) | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| RU2199339C2 (ru) | 2001-02-23 | 2003-02-27 | Общество с ограниченной ответственностью "Биотех" | Способ лечения рассеянного склероза |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
| ES2316758T3 (es) | 2002-05-16 | 2009-04-16 | Novartis Ag | Uso de aglutinantes del receptor edg en el cancer. |
| EP1511473B8 (en) * | 2002-05-27 | 2013-07-24 | Novartis AG | Bis-aromatic alkanols |
| TWI335311B (en) * | 2002-09-24 | 2011-01-01 | Novartis Ag | Organic compounds |
| KR20040048231A (ko) * | 2002-12-02 | 2004-06-07 | 주식회사 두산 | 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트 |
| FR2848495B1 (fr) * | 2002-12-12 | 2006-11-17 | Sidel Sa | Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique |
| KR101367574B1 (ko) | 2003-04-08 | 2014-02-25 | 미쓰비시 타나베 파마 코퍼레이션 | Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물 |
| PE20050158A1 (es) | 2003-05-19 | 2005-05-12 | Irm Llc | Compuestos inmunosupresores y composiciones |
| JP4728962B2 (ja) * | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| UA74941C2 (en) | 2004-04-26 | 2006-02-15 | Fos Internat S A | A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same |
| WO2005113330A1 (en) | 2004-05-05 | 2005-12-01 | Adler, Richard, S. | Systems and methods for protecting ship from attack on the surface or under water |
| US7354580B2 (en) * | 2004-06-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| CN102397542B (zh) * | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| KR20130041385A (ko) | 2004-11-29 | 2013-04-24 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| MX2007007165A (es) * | 2004-12-17 | 2007-08-14 | Genentech Inc | Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior. |
| RU2278687C1 (ru) | 2005-06-16 | 2006-06-27 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) | Способ лечения ремиттирующего рассеянного склероза |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
| GB2527550B (en) | 2014-06-25 | 2016-09-21 | Cook Medical Technologies Llc | Implantable medical device with lumen constriction |
-
2006
- 2006-06-27 GB GBGB0612721.1A patent/GB0612721D0/en not_active Ceased
-
2007
- 2007-06-25 ES ES15177166T patent/ES2887042T3/es active Active
- 2007-06-25 PT PT151771664T patent/PT2959894T/pt unknown
- 2007-06-25 DE DE15177166.4T patent/DE15177166T1/de active Pending
- 2007-06-25 KR KR1020157030213A patent/KR20150122812A/ko not_active Ceased
- 2007-06-25 RU RU2009102278A patent/RU2617502C2/ru active
- 2007-06-25 HU HUE15177166A patent/HUE059922T4/hu unknown
- 2007-06-25 KR KR1020217001928A patent/KR20210010956A/ko not_active Ceased
- 2007-06-25 SI SI200732191T patent/SI2959894T1/sl unknown
- 2007-06-25 EP EP13186359.9A patent/EP2698154A1/en not_active Withdrawn
- 2007-06-25 EP EP07764828A patent/EP2037906A1/en not_active Withdrawn
- 2007-06-25 AU AU2007264031A patent/AU2007264031C1/en active Active
- 2007-06-25 PL PL15177166.4T patent/PL2959894T3/pl unknown
- 2007-06-25 BR BRPI0713985-3A patent/BRPI0713985A2/pt not_active Application Discontinuation
- 2007-06-25 KR KR1020177034918A patent/KR20170138583A/ko not_active Ceased
- 2007-06-25 WO PCT/EP2007/005597 patent/WO2008000419A1/en not_active Ceased
- 2007-06-25 CN CN2007800236012A patent/CN101478961B/zh not_active Expired - Fee Related
- 2007-06-25 DK DK15177166.4T patent/DK2959894T3/da active
- 2007-06-25 LT LTEP2959894T patent/LT2959894T/lt unknown
- 2007-06-25 EP EP15177166.4A patent/EP2959894B1/en active Active
- 2007-06-25 US US12/303,765 patent/US20100168078A1/en not_active Abandoned
- 2007-06-25 KR KR1020097001390A patent/KR20090024281A/ko not_active Withdrawn
- 2007-06-25 KR KR1020147010290A patent/KR20140069178A/ko not_active Withdrawn
- 2007-06-25 MX MX2008016133A patent/MX2008016133A/es not_active Application Discontinuation
- 2007-06-25 JP JP2009516964A patent/JP2009541386A/ja active Pending
- 2007-06-25 EP EP20208442.2A patent/EP3797765A1/en not_active Withdrawn
- 2007-06-25 CN CN201310446846.3A patent/CN103550195A/zh active Pending
- 2007-06-25 KR KR1020197007465A patent/KR20190030776A/ko not_active Ceased
- 2007-06-25 CA CA2653569A patent/CA2653569C/en active Active
-
2008
- 2008-12-16 MX MX2022008950A patent/MX2022008950A/es unknown
- 2008-12-16 MX MX2019012750A patent/MX2019012750A/es unknown
-
2011
- 2011-04-21 AU AU2011201844A patent/AU2011201844B2/en active Active
- 2011-05-31 US US13/149,468 patent/US8741963B2/en active Active
-
2013
- 2013-01-24 AU AU2013200356A patent/AU2013200356B2/en active Active
- 2013-04-02 JP JP2013076909A patent/JP2013166761A/ja active Pending
-
2014
- 2014-04-21 US US14/257,342 patent/US9187405B2/en active Active
-
2016
- 2016-04-26 JP JP2016087703A patent/JP2016185957A/ja not_active Withdrawn
- 2016-12-01 AU AU2016266058A patent/AU2016266058A1/en not_active Abandoned
-
2018
- 2018-02-08 JP JP2018021389A patent/JP2018109018A/ja not_active Withdrawn
- 2018-03-28 AU AU2018202210A patent/AU2018202210A1/en not_active Abandoned
-
2019
- 2019-05-09 JP JP2019089217A patent/JP6931019B2/ja active Active
- 2019-08-22 AU AU2019219818A patent/AU2019219818A1/en not_active Abandoned
-
2020
- 2020-10-21 JP JP2020176666A patent/JP7258832B2/ja active Active
-
2021
- 2021-04-20 AU AU2021202395A patent/AU2021202395A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061697A patent/JP2023098949A/ja active Pending
-
2024
- 2024-10-01 JP JP2024172795A patent/JP2025016462A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541386A5 (enExample) | ||
| ECSP10010336A (es) | Derivados de piridina | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| JP2006526031A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
| CY1112826T1 (el) | [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες | |
| NO20054206L (no) | Bifenylderivater | |
| JP2006509749A5 (enExample) | ||
| JP2012530758A5 (enExample) | ||
| JP2010520214A5 (enExample) | ||
| JP2005522432A5 (enExample) | ||
| NO20076481L (no) | Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister | |
| WO2008137809A3 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| CA2600409A1 (en) | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds | |
| EA201001645A1 (ru) | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора | |
| JP2017509611A5 (enExample) | ||
| JP2008515907A5 (enExample) | ||
| CL2007002349A1 (es) | Compuestos derivados de pirazolo[3,4-b]piridina; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de una enfermedad inflamatoria y/o alergica, tal como epoc, asma y rinitis. | |
| JP2011519845A5 (enExample) | ||
| JP2010510263A5 (enExample) | ||
| JP2009505973A5 (enExample) | ||
| AR074314A1 (es) | Pirrolidinas, antagonistas de ep2 | |
| JP2008505938A5 (enExample) |